Q6DFV7
Gene name |
Ncoa7 |
Protein name |
Nuclear receptor coactivator 7 |
Names |
|
Species |
Mus musculus (Mouse) |
KEGG Pathway |
mmu:211329 |
EC number |
|
Protein Class |
|
Descriptions
The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.
Autoinhibitory domains (AIDs)
Target domain |
|
Relief mechanism |
|
Assay |
cis-regPred |
Accessory elements
No accessory elements
Autoinhibited structure
Activated structure
1 structures for Q6DFV7
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| AF-Q6DFV7-F1 | Predicted | AlphaFoldDB |
60 variants for Q6DFV7
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
| rs3389094431 | 22 | K>N | No | EVA | |
| rs33753991 | 38 | S>A | No | EVA | |
| rs33753989 | 49 | N>K | No | EVA | |
| rs215013648 | 59 | N>H | No | EVA | |
| rs3389086436 | 60 | V>SDG* | No | EVA | |
| rs3389104691 | 61 | T>R | No | EVA | |
| rs3389094394 | 69 | D>H | No | EVA | |
| rs3401071502 | 78 | Q>L | No | EVA | |
| rs3389094923 | 79 | L>* | No | EVA | |
| rs3389086428 | 100 | T>S | No | EVA | |
| rs3389094875 | 104 | K>* | No | EVA | |
| rs3389073632 | 104 | K>I | No | EVA | |
| rs1135251567 | 107 | K>Q | No | EVA | |
| rs253370919 | 109 | M>V | No | EVA | |
| rs1134208188 | 111 | Q>H | No | EVA | |
| rs1131780894 | 113 | P>S | No | EVA | |
| rs1135382103 | 115 | G>S | No | EVA | |
| rs3389095763 | 126 | T>S | No | EVA | |
| rs229698047 | 136 | V>I | No | EVA | |
| rs3401019210 | 177 | P>R | No | EVA | |
| rs3401020591 | 177 | P>T | No | EVA | |
| rs3389081686 | 197 | D>N | No | EVA | |
| rs3389037167 | 233 | T>S | No | EVA | |
| rs3389099488 | 327 | K>N | No | EVA | |
| rs3389103822 | 337 | Q>K | No | EVA | |
| rs33756807 | 348 | A>V | No | EVA | |
| rs33756806 | 352 | R>G | No | EVA | |
| rs242687872 | 359 | E>K | No | EVA | |
| rs33755993 | 360 | R>H | No | EVA | |
| rs257265368 | 366 | E>Q | No | EVA | |
| rs265146455 | 367 | P>T | No | EVA | |
| rs246572107 | 395 | L>P | No | EVA | |
| rs224477153 | 398 | R>H | No | EVA | |
| rs33755991 | 416 | D>E | No | EVA | |
| rs250308014 | 449 | G>R | No | EVA | |
| rs218829028 | 449 | G>V | No | EVA | |
| rs232821190 | 451 | H>L | No | EVA | |
| rs249561582 | 451 | H>N | No | EVA | |
| rs219422332 | 463 | S>P | No | EVA | |
| rs33755989 | 485 | A>G | No | EVA | |
| rs3400452123 | 485 | A>S | No | EVA | |
| rs3400452009 | 486 | E>Q | No | EVA | |
| rs33755985 | 497 | H>Q | No | EVA | |
| rs3399917909 | 516 | D>G | No | EVA | |
| rs33755103 | 549 | I>L | No | EVA | |
| rs33755101 | 572 | D>G | No | EVA | |
| rs262511183 | 588 | P>S | No | EVA | |
| rs3389099516 | 600 | I>V | No | EVA | |
| rs3389094414 | 724 | V>SDG* | No | EVA | |
| rs3389069002 | 727 | E>G | No | EVA | |
| rs3399916799 | 739 | S>G | No | EVA | |
| rs3389095756 | 744 | K>M | No | EVA | |
| rs3389095756 | 744 | K>T | No | EVA | |
| rs3389068997 | 762 | S>C | No | EVA | |
| rs216331807 | 779 | P>T | No | EVA | |
| rs3389095722 | 842 | Q>* | No | EVA | |
| rs3389086432 | 849 | T>I | No | EVA | |
| rs3389097191 | 852 | F>S | No | EVA | |
| rs3389097135 | 865 | F>S | No | EVA | |
| rs3389103795 | 897 | G>E* | No | EVA |
No associated diseases with Q6DFV7
1 GO annotations of cellular component
| Name | Definition |
|---|---|
| nucleus | A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent. |
2 GO annotations of molecular function
| Name | Definition |
|---|---|
| nuclear receptor binding | Binding to a nuclear receptor protein. Nuclear receptor proteins are DNA-binding transcription factors which are regulated by binding to a ligand. |
| nuclear receptor coactivator activity | A transcription coactivator activity that activates or increases the transcription of specific gene sets via binding to a DNA-bound nuclear receptor, either on its own or as part of a complex. Coactivators often act by altering chromatin structure and modifications. For example, one class of transcription coregulators modifies chromatin structure through covalent modification of histones. A second class remodels the conformation of chromatin in an ATP-dependent fashion. A third class modulates interactions of DNA-bound DNA-binding transcription factors with other transcription coregulators. A fourth class of coactivator activity is the bridging of a DNA-binding transcription factor to the general (basal) transcription machinery. The Mediator complex, which bridges sequence-specific DNA binding transcription factors and RNA polymerase, is also a transcription coactivator. |
6 GO annotations of biological process
| Name | Definition |
|---|---|
| negative regulation of cellular response to oxidative stress | Any process that stops, prevents or reduces the frequency, rate or extent of cellular response to oxidative stress. |
| negative regulation of oxidative stress-induced neuron death | Any process that stops, prevents or reduces the frequency, rate or extent of oxidative stress-induced neuron death. |
| negative regulation of peptidyl-cysteine S-nitrosylation | Any process that stops, prevents or reduces the frequency, rate or extent of peptidyl-cysteine S-nitrosylation. |
| positive regulation of transcription by RNA polymerase II | Any process that activates or increases the frequency, rate or extent of transcription from an RNA polymerase II promoter. |
| regulation of transcription by RNA polymerase II | Any process that modulates the frequency, rate or extent of transcription mediated by RNA polymerase II. |
| response to oxidative stress | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of oxidative stress, a state often resulting from exposure to high levels of reactive oxygen species, e.g. superoxide anions, hydrogen peroxide (H2O2), and hydroxyl radicals. |
| 10 | 20 | 30 | 40 | 50 | 60 |
| MDTKEEKKEQ | KERKQSYFAR | LKKKKQAKQN | AEIVSAASSK | SRSGKDDANS | DILEQDKFNV |
| 70 | 80 | 90 | 100 | 110 | 120 |
| TAEGDHSTDD | KKKRKSNQLK | EIRRTELKRY | YSVDDNQNKT | HDKKEKKMMV | QKPQGTMEYT |
| 130 | 140 | 150 | 160 | 170 | 180 |
| AGSQDTLNSV | ALKFNVTPNK | LVELNKLFTH | TIVPGQVLFV | PDANISSSTI | QLSSSTPGAT |
| 190 | 200 | 210 | 220 | 230 | 240 |
| VSPSSSDAEY | DKLPDADLAR | KALKPIERVL | SSTSEEDEPG | VVKFLKMNCR | YFTDGKGVVG |
| 250 | 260 | 270 | 280 | 290 | 300 |
| GVMIVTPNNI | MFDPHKSDPL | VIENGCEEYG | LICPMEEVVS | IALYSDISHM | KIKDALPSDL |
| 310 | 320 | 330 | 340 | 350 | 360 |
| PRDLCPLYRP | GEWEDLASEK | DINPFSKFKS | INKEKRQQNG | ERTLALDAKS | VRSPEESTER |
| 370 | 380 | 390 | 400 | 410 | 420 |
| TCTRIEPPDN | SELWKLKNLQ | SSRGTTSESP | SVTQLSMRAA | LEPTAKENCL | LKGDEDFVDL |
| 430 | 440 | 450 | 460 | 470 | 480 |
| EELSSQPESG | INKGDATKEC | LSYDQKKDGP | HTVMSAKKGH | VQSAQEVMGP | ESDTELKGAL |
| 490 | 500 | 510 | 520 | 530 | 540 |
| DLETAEKQDE | APEVDKHSGS | PENLGESTLN | IHEDLDKIKL | IEFYLNKNKE | GSQLLENVQK |
| 550 | 560 | 570 | 580 | 590 | 600 |
| SELSDRKSIE | PGGIDITLSS | SLPQAGDSPP | EDNKEPGTLW | VKGGETLPLK | LDPSAEETVI |
| 610 | 620 | 630 | 640 | 650 | 660 |
| NNKEVLDSLG | SSLDKMCHSA | QMDNKSEIQL | WLLKRIQVPI | EDILPSKEEK | SKTPPMFLCI |
| 670 | 680 | 690 | 700 | 710 | 720 |
| KVGKPMRKSF | ASHTATMVQQ | YSKRRKQPEY | WFAVPRERVD | HLYTFFVQWS | PDVYGKDAKE |
| 730 | 740 | 750 | 760 | 770 | 780 |
| QGFVVVEKEE | LNMIDNFFSE | PTTKSWEIIT | VEEAKRRKST | CSYYEEEEEE | EEGLPILQPH |
| 790 | 800 | 810 | 820 | 830 | 840 |
| SALLENMHIE | QLARRLPARV | QGYPWRLAYS | TLEHGTSLKT | LYRKSASLDS | PVLLVIKDMD |
| 850 | 860 | 870 | 880 | 890 | 900 |
| NQIFGAYATH | PFKFSDHYYG | TGETFLYTFS | PNFKVFKWSG | ENSYFINGDI | SSLELGGGGG |
| 910 | 920 | 930 | 940 | ||
| RFGLWLDADL | YHGRSNSCST | FNNDILSKKE | DFIVQDLEVW | TFE |